Scotiabank Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $51
Rocket Pharmaceuticals to Present Updated Data From the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating
Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $62 Price Target
Scotiabank Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Raises Target Price to $51
J.P. Morgan Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $49